Active Ingredient History
Tigecycline (INN) is an antibiotic used to treat a number of bacterial infections. It is a first in class glycylcycline that is administered intravenously. For the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes and Bacteroides fragilis. Complicated intra-abdominal infections caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros. Tigecycline, a glycylcycline, inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. Tigecycline carries a glycylamido moiety attached to the 9-position of minocycline. The substitution pattern is not present in any naturally occurring or semisynthetic tetracycline and imparts certain microbiologic properties to tigecycline. In general, tigecycline is considered bacteriostatic; however, TYGACIL has demonstrated bactericidal activity against isolates of S. pneumoniae and L. pneumophila. In vitro studies have not demonstrated antagonism between tigecycline and other commonly used antibacterials. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Intraabdominal Infections (approved 2006)
Pneumonia, Bacterial (approved 2006)
Staphylococcal Skin Infections (approved 2006)
Abdominal Abscess (Phase 4)
Abdominal Injuries (Phase 2/Phase 3)
Abscess (Phase 2)
Appendicitis (Phase 4)
Bacteremia (Phase 4)
Bacterial Infections (Phase 4)
Blood-Borne Infections (Phase 3)
Catheter-Related Infections (Phase 4)
Cholecystitis (Phase 4)
Community-Acquired Infections (Phase 3)
Cross Infection (Phase 4)
Dermatology (Phase 2)
Diabetic Foot (Phase 3)
Diverticulitis (Phase 4)
Gram-Negative Bacterial Infections (Phase 3)
Gram-Positive Bacterial Infections (Phase 3)
Healthcare-Associated Pneumonia (Phase 3)
Healthy Volunteers (Phase 1)
Hematologic Neoplasms (Phase 4)
Infections ()
Intraabdominal Infections (Phase 4)
Kidney Failure, Chronic (Phase 1)
Klebsiella pneumoniae (Phase 4)
Leukemia (Phase 4)
Leukemia, Myeloid, Acute (Phase 1)
Liver Cirrhosis, Biliary (Phase 1)
Lung Diseases (Phase 2/Phase 3)
Lymphoma (Phase 4)
Methicillin Resistance (Phase 3)
Multiple Myeloma (Phase 4)
Myelodysplastic Syndromes (Phase 4)
Obesity (Phase 4)
Osteomyelitis (Phase 3)
Peritonitis (Phase 4)
Pneumonia, Bacterial (Phase 3)
Pneumonia, Ventilator-Associated (Phase 3)
Pyelonephritis (Phase 3)
Skin Diseases (Phase 3)
Skin Diseases, Bacterial (Phase 4)
Skin Diseases, Infectious (Phase 4)
Staphylococcal Infections (Phase 4)
Staphylococcal Skin Infections (Phase 2)
Stem Cell Transplantation (Phase 4)
Surgical Wound Infection (Phase 3)
Urinary Tract Infections (Phase 3)
Vancomycin Resistance (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
